Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Xylome is a synthetic biology company based in Madison, Wisconsin, specializing in the metabolic engineering of non-conventional yeasts to produce sustainable lipids and specialty chemicals. The company leverages its proprietary 'Yali' platform, centered on the yeast Yarrowia lipolytica, to convert agricultural residues and industrial byproducts into high-value alternatives for palm oil and petroleum-based ingredients. Their flagship product, Yoil, serves as a sustainable substitute for palm oil in food and cosmetic applications, addressing significant environmental concerns related to traditional palm oil production. Additionally, Xylome develops advanced yeast strains for the efficient fermentation of xylose into ethanol and other biochemicals. By integrating deep expertise in yeast genetics with scalable fermentation technology, Xylome provides renewable solutions for the global chemical, nutritional, and energy markets.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Xylome.